- Home
- /
- Treatment
- /
- Page 125
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
L-5-hydroxytryptophan | Tetrahydrobiopterin deficiency | Watson Laboratories, Inc.;311 Bonnie Circle, P.O. Box 1900;Corona, California, 91718 | January 20, 1999 | |
Interferon beta-1a (recombinant human) | Pulmonary fibrosis | Biogen Idec, Inc.;14 Cambridge Center;Cambridge, Massachusetts, 02142 | January 7, 1999 | |
Papain, trypsin, and chymotrypsin | Multiple myeloma | Marlyn Nutraceuticals, Inc.;14851 N. Scottsdale Rd.;Scottsdale, Arizona, 85254 | December 21, 1998 | |
Polyethylene glycol-modified uricase | Tumor lysis syndrome in cancer patients undergoing chemotherapy | EnzymeRx, LLC;17 Arcadian Avenue, Suite 104;Paramus, New Jersey, 07652 | December 21, 1998 | |
Deferoxamine starch conjugate | Beta-thalassemia | Biomedical Frontiers, Inc.;108710th Ave., S.E.;Minneapolis, Minnesota, 55414 | December 21, 1998 | |
Follitropin alfa, recombinant | For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. | EMD Serono, Inc.;One Technology Place;Rockland, Massachusetts, 02370 | December 21, 1998 | |
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma | B-cell non-Hodgkin's lymphoma | Peregrine Pharmaceuticals, Inc.;14272 Franklin Ave., Suite 100;Tustin, California, 92780 | November 27, 1998 | |
Xenogeneic hepatocytes | Severe liver failure | Circe Biomedical, Inc.;99 Hayden Ave.;Lexington, Massachusetts, 02421 | November 27, 1998 | |
Aldesleukin | For the treatment non-Hodgkin's lymphoma | Prometheus Laboratories, Inc.;9410 Carroll Park Drive;San Diego, California, 92121 | November 24, 1998 | |
Amifostine | For the reduction of the incidence and severity of toxicities associated with cisplatin administration | Clinigen Group plc;Pitcairn House, Crown Square, DE14 2WW; | November 24, 1998 | |
MN14 monoclonal antibody to carcinoembryonic antigen | Pancreatic cancer | Immunomedics, Inc.;300 The American Road;Morris Plains, New Jersey, 07950 | November 24, 1998 | |
Humanized anti-CD2 monoclonal antibody | Graft Versus Host Disease | MedImmune, Inc.;35 West Watkins Mill Rd.;Gaithersburg, Maryland, 20878 | November 13, 1998 | |
Oxypurinol | Hyperuricemia in patients intolerant to allopurinol | Cardiome Pharma Corp.;3650 Westbrook Mall, Vancouver, B.C.; | November 9, 1998 | |
Doxorubicin liposome | Ovarian cancer | Alza Corporation;1550 Plymouth St., PO Box 7210;Mountain View, California, 94039 | November 4, 1998 | |
Etanercept | Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs | Immunex Corporation;One Amgen Center Drive;Thousand Oaks, California, 91320 | October 27, 1998 | |
P1, P4-Di(uridine 5′-tetraphosphate), tetrasodium salt | Cystic fibrosis | Inspire Pharmaceuticals, Inc.;4222 Emperor Blvd., Suite 470;Durham, North Carolina, 27703 | October 27, 1998 | |
Temozolomide | Advanced metastatic melanoma | Merck & Company;2000 Galloping Hill Rd.;Kenilworth, New Jersey, 07033 | October 14, 1998 | |
Methoxsalen | For use in conjunction with the UVAR photopheresis system to treat graft versus host disease | Therakos, Inc.;1001 Route 202;Raritan, New Jersey, 08869 | October 14, 1998 | |
Mecamylamine | Tourette syndrome | Targacept, Inc.;200 East First St., Suite 300;Winston-Salem, North Carolina, 27101 | October 14, 1998 | |
Thalidomide | Multiple myeloma | Celgene Corporation;7 Powder Horn Dr.;Warren | October 14, 1998 | |
Recombinant humanized MAb 5c8 | Hemophilia A | Biogen, Inc.;14 Cambridge Center;Cambridge, Massachusetts, 02142 | October 14, 1998 | |
MN14 monoclonal antibody to carcinoembryonic antigen | Small cell lung cancer | Immunomedics, Inc.;300 The American Road;Morris Plains, New Jersey, 07950 | September 18, 1998 | |
Humanized anti-human CD2 MAb | For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants | Biotransplant, Inc.;Building 75, 3rd. Ave., Charlestown Navy Yard;Charlestown, Massachusetts, 02129 | September 17, 1998 | |
3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one | Kaposi sarcoma | Sugen, Inc.;230 East Grand Ave.;South San Francisco, California, 94080 | September 11, 1998 | |
Dexamethasone intravitreal implant | Panuveitis | Allergan;2525 Dupont Drive;Irvine, California, 92623 | September 11, 1998 |